Drug Profile

CY 3018

Alternative Names: CY-3018

Latest Information Update: 01 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cyclerion Therapeutics
Class
Mechanism of Action Soluble guanylyl cyclase agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical CNS disorders

Most Recent Events

01 Oct 2025 CY 3018 is still in preclinical trials for CNS-disorders in USA (Cyclerion Therapeutics website, September 2025,
28 May 2025 No recent reports of development identified for preclinical development in CNS-disorders in USA
31 Jul 2023 Tisento Therapeutics acquires zagociguat from Cyclerion Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com